<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="sca13" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">sca13</book-part-id>
      <title-group>
        <title>Spinocerebellar Ataxia Type 13</title>
        <alt-title alt-title-type="alt-title">Synonym: SCA13</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pulst</surname>
            <given-names>Stefan M</given-names>
          </name>
          <degrees>MD</degrees>
          <email>stefan.pulst@hsc.utah.edu</email>
          <aff>Department of Neurology <break/>University of Utah <break/>Salt Lake City, Utah</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2006-11-09" date-type="created">
          <day>9</day>
          <month>11</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2012-03-01" date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="sca12" document-type="chapter">Spinocerebellar Ataxia Type 12</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="sca14" document-type="chapter">Spinocerebellar Ataxia Type 14</related-object>
      <abstract id="sca13.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>In the families described to date, the phenotype of spinocerebellar ataxia type 13 (SCA13) has ranged from slowly progressive childhood-onset cerebellar gait ataxia associated with cerebellar dysarthria and often accompanied by mild intellectual disability and occasional seizures to adult-onset progressive ataxia. Life span is not shortened and many persons live beyond age 70 years, but assistance with gait may be required as the disease progresses.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis is based on clinical findings and molecular genetic testing of <italic toggle="yes">KCNC3</italic> (also known as <italic toggle="yes">Kv3.3</italic>), the only gene known to be associated with SCA13.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Antiepileptic drugs for seizures; canes, walkers and other adaptive devices to help prevent falls; speech therapy and communication devices; feeding assessment if dysphagia is present.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Weight control.</p>
          <p><italic toggle="yes">Surveillance:</italic> Evaluation by a neurologist at least annually, and more often in the event of acute exacerbation.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Alcohol and sedating drugs because they can exacerbate ataxia.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>SCA13 is inherited in an autosomal dominant manner. Too little data are available to estimate the proportion of cases resulting from a new pathogenic variant. Each child of an individual with SCA13 has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for SCA13 is possible if the pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="sca13.Diagnosis">
        <title>Diagnosis</title>
        <sec id="sca13.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The phenotype of spinocerebellar ataxia type 13 (SCA13) overlaps with that of other infantile or adult-onset ataxias. The correct diagnosis can only be established by molecular genetic testing of <italic toggle="yes">KCNC3</italic>.</p>
        </sec>
        <sec id="sca13.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">KCNC3</italic> (also known as <italic toggle="yes">Kv3.3</italic>) is the only gene in which pathogenic variants are known to cause SCA13.</p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sequence analysis.</bold> Direct sequencing of all four coding exons and flanking splice sites of <italic toggle="yes">KCNC3</italic> is the most sensitive approach for identifying pathogenic variants. Because data are limited, the proportion of pathogenic variants identified is not known. Note: As all known pathogenic variants cluster in exon 2, it is reasonable to begin by sequencing this exon.</p>
            </list-item>
          </list>
          <table-wrap id="sca13.T.summary_of_molecular_genetic_tes" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Spinocerebellar Ataxia Type 13</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">KCNC3</italic>
                  </td>
                  <td headers="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_sca13.T.summary_of_molecular_genetic_tes_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="sca13.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="sca13" object-id="sca13.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="sca13.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="sca13.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="sca13.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
              </fn>
              <fn id="sca13.TF.1.4">
                <label>4. </label>
                <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="sca13.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The testing strategy for hereditary cerebellar ataxias is discussed in the <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Hereditary Ataxia Overview</related-object>.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="sca13.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="sca13.Clinical_Description">
          <title>Clinical Description</title>
          <p>In the families described to date, the spinocerebellar ataxia type 13 (SCA13) phenotype has ranged from early-onset ataxia with little progression, often accompanied by mild intellectual disability and occasional seizures [<xref ref-type="bibr" rid="sca13.REF.hermanbert.2000.229">Herman-Bert et al 2000</xref>, <xref ref-type="bibr" rid="sca13.REF.figueroa.2011.e17811">Figueroa et al 2011</xref>], to adult-onset progressive ataxia [<xref ref-type="bibr" rid="sca13.REF.waters.2005.1111">Waters et al 2005</xref>, <xref ref-type="bibr" rid="sca13.REF.waters.2008.165">Waters &#x00026; Pulst 2008</xref>, <xref ref-type="bibr" rid="sca13.REF.figueroa.2010.191">Figueroa et al 2010</xref>]. Onset has ranged from infancy to 60 years.</p>
          <p>In the family described by <xref ref-type="bibr" rid="sca13.REF.hermanbert.2000.229">Herman-Bert et al [2000]</xref>, seven women and a four-year-old boy exhibited slowly progressive childhood-onset cerebellar gait ataxia associated with cerebellar dysarthria, moderate intellectual disability (IQ 62-76), and mild developmental delays in motor acquisition. Nystagmus and pyramidal signs were also observed in some.</p>
          <p>Life span is not shortened and many persons live beyond age 70 years; assistance with gait may be required as the disease progresses.</p>
          <p>Brain MRI in all affected persons has shown mild to moderately severe cerebellar atrophy that is primarily midline. This has been evident as early as age three years. Atrophy of the brain stem or cerebral cortex is not observed.</p>
        </sec>
        <sec id="sca13.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The known pathogenic variants in <italic toggle="yes">KCNC3</italic> are associated with different phenotypes; however, data are too limited to make any genotype-phenotype correlations at this time.</p>
          <list list-type="bullet">
            <list-item>
              <p>The p.Arg420His variant was associated with adult-onset progressive ataxia in one family [<xref ref-type="bibr" rid="sca13.REF.waters.2005.1111">Waters et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>The p.Phe448Leu variant is associated with childhood onset ataxia and often intellectual disability and seizures.</p>
            </list-item>
            <list-item>
              <p>The p.Arg423His variant has also been associated with mild cognitive impairment and seizures.</p>
            </list-item>
          </list>
        </sec>
        <sec id="sca13.Penetrance">
          <title>Penetrance</title>
          <p><italic toggle="yes">KCNC3</italic> pathogenic variants appear to be fully penetrant in the families described.</p>
        </sec>
        <sec id="sca13.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation is not observed.</p>
        </sec>
        <sec id="sca13.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of SCA13 is not known. Only one person with SCA13 was identified in a cohort of 327 probands with ataxia [<xref ref-type="bibr" rid="sca13.REF.figueroa.2011.e17811">Figueroa et al 2011</xref>].</p>
        </sec>
      </sec>
      <sec id="sca13.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are associated with mutation of <italic toggle="yes">KCNC3</italic>.</p>
      </sec>
      <sec id="sca13.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Persons with spinocerebellar ataxia type 13 (SCA13) may present with ataxia that is indistinguishable from other adult-onset inherited or acquired ataxias (see <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Ataxia Overview</related-object>).</p>
      </sec>
      <sec id="sca13.Management">
        <title>Management</title>
        <sec id="sca13.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with spinocerebellar ataxia type 13 (SCA13), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medical history</p>
            </list-item>
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>EEG</p>
            </list-item>
            <list-item>
              <p>Formal neuropsychological tests for individuals with problems in learning and social adaptation</p>
            </list-item>
            <list-item>
              <p>Speech pathology evaluation if dysarthria is atypical or severe enough to cause communication problems. For individuals with frequent choking or severe dysphagia, speech pathology evaluation may be important in assessing aspiration risks.</p>
            </list-item>
          </list>
        </sec>
        <sec id="sca13.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Epileptic seizures can be improved by treatment with anticonvulsive medications.</p>
          <p>Although neither exercise nor physical therapy has been shown to stem the progression of incoordination or muscle weakness, individuals should maintain activity.</p>
          <p>Canes and walkers help prevent falls. Modification of the home with such conveniences as grab bars, raised toilet seats, and ramps to accommodate motorized chairs may be necessary. Weighted eating utensils and dressing hooks help maintain a sense of independence.</p>
          <p>Speech therapy and communication devices such as writing pads and computer-based devices may benefit those with dysarthria.</p>
          <p>When dysphagia becomes troublesome, video esophagrams can identify the consistency of food least likely to trigger aspiration.</p>
          <p>Note: Tremor-controlling drugs are not effective for cerebellar tremors.</p>
        </sec>
        <sec id="sca13.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>No dietary factor has been shown to curtail symptoms; however, vitamin supplements are recommended, particularly if caloric intake is reduced.</p>
          <p>Weight control is important because obesity can exacerbate difficulties with ambulation.</p>
        </sec>
        <sec id="sca13.Surveillance">
          <title>Surveillance</title>
          <p>Evaluation by a neurologist is indicated annually, or more often in the event of an acute exacerbation.</p>
        </sec>
        <sec id="sca13.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Alcohol and sedating drugs can exacerbate ataxia.</p>
        </sec>
        <sec id="sca13.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="sca13.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="sca13.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Weight gain during pregnancy can further impair gait ataxia.</p>
        </sec>
        <sec id="sca13.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="sca13.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="sca13.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Spinocerebellar ataxia type 13 (SCA13) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="sca13.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Only two families with SCA13 have been described; the individuals diagnosed with SCA13 had an affected parent.</p>
            </list-item>
            <list-item>
              <p>As the <italic toggle="yes">KCNC3</italic> pathogenic variants identified to date are private (i.e., occurring in only a single family), <italic toggle="yes">de novo</italic> pathogenic variants may arise in this gene. Too few unselected cases have been studied to derive a reliable estimate of the proportion of cases that result from <italic toggle="yes">de novo</italic> mutation.</p>
            </list-item>
            <list-item>
              <p>It is recommended that both parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant be evaluated using molecular genetic testing.</p>
            </list-item>
            <list-item>
              <p>Note: The family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, late onset of the disease in the affected parent, or reduced penetrance; therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected and a pathogenic variant cannot be detected in the DNA of either parent, the risk to the sibs of a proband is probably low; however, no such cases have been studied to date. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with SCA13 has a 50% chance of inheriting the pathogenic variant.</p>
          <p>
            <bold>Other family members of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has a pathogenic variant, his or her family members are at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="sca13.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has clinical evidence of the disorder or the pathogenic variant, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="sca13.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">KCNC3</italic> pathogenic variant has been identified in the family, prenatal diagnosis for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom prenatal testing</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="sca13.Resources">
        <title>Resources</title>
      </sec>
      <sec id="sca13.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">KCNC3</italic> (reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_004977.2">NM_004977.2</ext-link>) comprises four coding exons. The fifth exon encodes the majority of the relatively long 3' UTR. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="sca13" object-id="sca13.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> The substitution c.788G&#x0003e;A (p.Gly263Asp) appears to be a common benign variant [<xref ref-type="bibr" rid="sca13.REF.figueroa.2011.e17811">Figueroa et al 2011</xref>].</p>
        <p><bold>Pathogenic allelic variants.</bold> The c.1259G&#x0003e;A (p.Arg420His) and c.1268G&#x0003e;A (p.Arg423His) pathogenic variants are located in the S4 voltage-sensor domain and the c.1344C&#x0003e;A (p.Phe448Leu) pathogenic variant in the S5 domain, which forms the ion pore.</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">KCNC3 (</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_004968.2">NP_004968.2</ext-link>) encodes a protein of 757 amino acid residues. It is a voltage-gated potassium channel with six membrane-spanning domains. Because this channel opens late during depolarization and is rapidly deactivated, it is important in regulation of the action potential and properties of bursting neurons [<xref ref-type="bibr" rid="sca13.REF.joho.2009.323">Joho &#x00026; Hurlock 2009</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The c.1259G&#x0003e;A (p.Arg420His) pathogenic variant results in a dominant-negative effect [<xref ref-type="bibr" rid="sca13.REF.waters.2006.447">Waters et al 2006</xref>]. The c.1344C&#x0003e;A (p.Phe448Leu) pathogenic variant results in a gain of function.</p>
      </sec>
      <sec id="sca13.References">
        <title>References</title>
        <sec id="sca13.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="sca13.Literature_Cited.reflist0">
            <ref id="sca13.REF.figueroa.2010.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garibyan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forlani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strzelczyk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;rk</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000fc;rr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papazian</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>KCNC3: phenotype, mutations, channel biophysics-a study of 260 familial ataxia patients.</article-title>
                <source>Hum Mutat.</source>
                <volume>31</volume>
                <fpage>191</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19953606</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.figueroa.2011.e17811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garibyan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranum</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papazian</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13).</article-title>
                <source>PLoS One</source>
                <volume>6</volume>
                <fpage>e17811</fpage>
                <pub-id pub-id-type="pmid">21479265</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.hermanbert.2000.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herman-Bert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netter</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rascol</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brassat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camuzat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schalling</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>229</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">10820125</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.joho.2009.323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joho</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurlock</surname>
                    <given-names>EC</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The role of Kv3-type potassium channels in cerebellar physiology and behavior.</article-title>
                <source>Cerebellum</source>
                <volume>8</volume>
                <fpage>323</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">19247732</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.waters.2005.1111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nolte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Advincula</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coon</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evidente</surname>
                    <given-names>VG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>An autosomal dominant ataxia maps to 19q13: Allelic heterogeneity of SCA13 or novel locus?</article-title>
                <source>Neurology</source>
                <volume>65</volume>
                <fpage>1111</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16135769</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.waters.2008.165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>SCA13.</article-title>
                <source>Cerebellum.</source>
                <volume>7</volume>
                <fpage>165</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18592334</pub-id>
              </element-citation>
            </ref>
            <ref id="sca13.REF.waters.2006.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minassian</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueroa</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bannister</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nolte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mock</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evidente</surname>
                    <given-names>VG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fee</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papazian</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulst</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.</article-title>
                <source>Nat Genet</source>
                <volume>38</volume>
                <fpage>447</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">16501573</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="sca13.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="sca13.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>1 March 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 November 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 September 2006 (smp) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
